Lead MRT™ drug platform product, RBX2660 is targeted at treating recurrent Clostridium difficile (C. diff.) infection. We are leveraging our years of knowledge and experience to develop MRT drug platform applications for other conditions that result from disruption of the gut microbiota.
Caution: Drug products are in development and investigational at this time. No product has yet been approved by the U.S. Food and Drug Administration.